NASDAQ · PMN
ProMIS Neurosciences Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for PMN: Nov 11, 2026
ProMIS Neurosciences Inc. Common Shares (ON) is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.26. The reported EPS for the same quarter last year was $-6.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.26 | $-0.98 | $-1.52 | 3 |
| Dec 2026 | $-1.24 | $-0.86 | $-1.52 | 3 |
| Mar 2027 | $-1.25 | $-0.68 | $-1.63 | 3 |
| Jun 2027 | $-1.00 | $-0.60 | $-1.65 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · MarketBeat- Zacks · Oct 29, 8:55 AM EDTWall Street Analysts Believe Promis Neurosciences (PMN) Could Rally 292.95%: Here's is How to TradeThe mean of analysts' price targets for Promis Neurosciences (PMN) points to a 293% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- Zacks · Oct 22, 7:40 AM EDTWill HCA Healthcare's Q3 Earnings Benefit From Higher Admissions?HCA's Q3 results could benefit from higher admissions, occupancy and inpatient revenues, but rising costs and fewer outpatient surgeries cloud the outlook.
- Zacks · Oct 21, 8:36 AM EDTCan Higher Admissions Offset Rising Costs in UHS' Q3 Earnings?Universal Health Services' Q3 revenues are expected to rise on higher patient admissions, but surging operating costs and wage pressures could weigh on earnings growth.
- RTTNews · Oct 6, 10:31 AM EDTProMIS Names Commercial Chief; PMN310 Data Due Q1 2027; Stock Down(RTTNews) – ProMIS Neurosciences Inc. (PMN) has appointed Ivana Rubino, Ph.D. as Chief Commercial Officer, adding an executive with more than 15 years of experience in Alzheimer's disease, neuroscience and clinical development, medical affairs and commercialization. The appointme
- MarketBeat · Aug 13, 10:04 PM EDTPromis Neurosciences Q2 Earnings Call HighlightsPromis Neurosciences (NASDAQ:PMN) reported second-quarter 2026 results and highlighted blinded six-month interim data from its Phase 1b PRECISE-AD study of PMN310, an investigational antibody for early Alzheimer’s disease. President and Chief Executive Officer Neil Warma said th
- RTTNews · Jul 31, 10:51 AM EDTWeekly Buzz:CIPLA, VTRS Win FDA Nod; BSX Cuts Jobs; ARGX Snaps Up FBRX; JNJ, GSK Strike Deals(RTTNews) – The healthcare sector delivered another eventful week, marked by major regulatory approvals, strategic partnerships, acquisitions, restructuring initiatives and significant clinical trial updates.
- RTTNews · Jul 28, 10:44 PM EDTTop Biotech Gainers: KNSA Soars On Q2 Results, TRIB, OPK On Watch, MPLT On The Mend?(RTTNews) – Today's top biotech gainers include Trinity Biotech, which recently completed reverse split; OPKO Health, driven by its second-quarter financial results and continued pipeline progress; Kiniksa Pharma, after raising its revenue outlook on strong commercial momentum; a
- MarketBeat · Jul 28, 2:04 PM EDTPromis Reports No ARIA-E in PMN310 Alzheimer’s Trial Interim DataPromis Neurosciences (NASDAQ:PMN) reported blinded six-month interim data from its Phase 1b PRECISE-AD trial of PMN310, an investigational antibody designed to selectively target toxic amyloid-beta oligomers in patients with mild cognitive impairment due to Alzheimer’s disease an
- RTTNews · Jul 28, 9:26 AM EDTProMIS Reports Positive Phase 1b Interim Data For PMN310 In Treating Alzheimer's; Stock Up 20%(RTTNews) – ProMIS Neurosciences Inc. (PMN), a clinical-stage biopharmaceutical company, on Tuesday released positive six-month interim data from the Phase 1b PRECISE-AD trial for PMN310 for treating mild cognitive impairment in patients of Alzheimer's disease.
- Zacks · Jul 27, 12:33 PM EDTWill Declining Medical Customers Affect Cigna's Q2 Earnings?CI's Q2 earnings are likely to face pressure from fewer insured medical customers and a higher MCR despite expected revenue growth.
- Zacks · Jul 23, 12:44 PM EDTCan Acute Care Strength Offset Universal Health's Rising Q2 Costs?UHS heads into Q2 with higher admissions and revenue growth expected, but rising labor and operating costs may limit earnings upside.
- Zacks · Jul 21, 11:44 AM EDTWill Lower Patient Days Affect Tenet Healthcare's Q2 Earnings?THC's Q2 performance is likely to have witnessed lower patient days, but higher revenue per admission and Ambulatory Care growth could help offset the pressure.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for ProMIS Neurosciences Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.